New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients

Journal of Pharmaceutical Sciences

Volumn 102, Issue 6, 2013, Pages 1836-1846

  Pilcer, Gabrielle ^a   Rosière, Rémi ^a   Traina, Karl ^b   Sebti, Thami ^c   Vanderbist, Francis ^c   Amighi, Karim ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b Aptis   (Belgium)

^c SMB SA   (Belgium)

Author keywords

Aerosol; Antibiotic; Clarithromycin; Dry powder inhaler; Formulation; Nanoparticles; Pulmonary drug delivery; Spray drying; Tobramycin

Indexed keywords

CLARITHROMYCIN; NANOPARTICLE; TOBRAMYCIN;

ARTICLE; DRUG CLEARANCE; DRUG SOLUBILITY; DRY POWDER; FLOW RATE; LASER DIFFRACTION; LUNG CAPACITY; LUNG FIBROSIS; LUNG FUNCTION; LUNG INFECTION; MELTING POINT; PARTICLE SIZE; POWDER FLOW; SOLID STATE; SPRAY DRYING; WATER CONTENT; WEIGHT CHANGE; X RAY POWDER DIFFRACTION;

EID: 84877920804     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23525     Document Type: Article

References (33)

1. Heijerman H, Westerman E, Conway S, Touw D, Döring G; consensus working group. 2009. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. J Cyst Fibros 8:295-315.
2. Govan JRW, Glass S. 1990. The microbiology and therapy of cystic fibrosis lung infections. Rev Med Microbiol 1:19-28.
3. Döring G, Hoiby N; Consensus Study Group. 2004. Early intervention and prevention of lung disease in cystic fibrosis: A European consensus. J Cyst Fibros 3:67-91.
4. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, Botzenhart K, Yankaskas JR, Randell S, Boucher RC, Döring G. 2002. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109:317-325.
5. Bates RD, Nahata MC. 1995. Aerosolized dornase alpha (rhDNase) in cystic fibrosis. J Clin Pharm Ther 20:313-315.
6. Parks Q, Young R, Poch K, Malcolm K, Vasil M, Nick J. 2009. Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: Human F-actin and DNA as targets for therapy. J Med Microbiol 58:492-502.
7. Tré-Hardy M, Vanderbist F, Traore H, Devleeschouwer M. 2008. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures. Int J Antimicrob Agents 3:329-336.
8. Tré-Hardy M, Macé C, El Manssouri N, Vanderbist F, Traore H, Devleeschouwer MJ. 2009. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: The importance of the biofilm model. Int J Antimicrob Agents 33(1):40-45.
9. Tré-Hardy M, Nagant C, El Manssouri N, Vanderbist F, Traore H, Vaneechoutte M, Dehaye JP. 2010. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model. Antimicrob Agents Chemother 54(10):4409-4415.
10. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. 2002. Pharmacokinetics and bioavailability of aerolized tobramycin in cystic fibrosis. Chest 122:219-226.
11. Newhouse M, Hirst P, Duddu S, Walter Y, Tarara T, Clark A, Weers J. 2003. Inhalation of a dry powder tobramycin pulmosphere formulation in healthy volunteers. Chest 124:360-366.
12. Pilcer G, Goole J, Van Gansbeke B, Blocklet D, Knoop C, Vanderbist F, Amighi K. 2008. Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients. Eur J Pharm Biopharm 68:413-421.
13. Pilcer G, Sebti T, Amighi K. 2006. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm Res 23(5):931-940.
14. Pilcer G, Vanderbist F, Amighi K. 2009. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery. Int J Pharm 365(1-2):162-169.
15. Kandemir O, Oztuna V, Milcan A, Bayramoglu A, Celik HH, Bayarslan C, Kaya A. 2005. Clarithromycin destroys biofilms and enhances bactericidal agents in the treatment of Pseudomonas aeruginosa osteomyelitis. Clin Orthop Relat Res 430:171-175.
16. Giamarellos-Bourboulis EJ, Antonopoulou A, Raftogiannis M, Koutoukas P, Tsaganos T, Tziortzioti V, Panagou C, Adamis T, Giamarellou H. 2006. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa. BMC Infect Dis 6:31.
17. Shinkai M, Lopez-Boado YS, Rubin BK. 2007. Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin. J Antimicrob Chemother 59:1096-1101.
18. Taki M, Marriott C, Zeng XM, Martin GP. 2008. An investigation into the influence of particle size, drug-drug and drug-excipient interactions on the aerodynamic deposition of drugs aerosolized from single and combination dry powder inhalers. In Respiratory drug delivery; Commonwealth University, Virginia, pp 589-592.
19. Kumon M, Kwok P, Adi H, Heng D, Chan H. 2010. Can low-dose combination products for inhalation be formulated in single crystalline particles? Eur J Pharm Sci 40:16-24.
20. Hannay M, Govind N, Ludzik A, Jansen R, Fletcher I. 2008. Overcoming the challenges of developing combination products in different inhalation device platforms. In Respiratory drug delivery; River Grove, Illinois: eds Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ & Young PM, pp 319-328.
21. Telko MJ, Hickey AJ. 2005. Dry powder inhaler formulation. Resp Care 50(9):1209-1227.
22. Pilcer G, Amighi K. 2010. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 392:1-19.
23. Sham J, Zhang Y, Finlay W, Roa W, Löbenberg R. 2004. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm 269:457-467.
24. Pilcer G, Vanderbist F, Amighi K. 2008. Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolized powder formulations. Int J Pharm 358(1-2):75-81.
25. Son YJ, McConville JT. 2009. Development of a standardized dissolution test method for inhaled pharmaceutical formulations. Int J Pharm 382:15-22.
26. Depreter F, Burniat A, Blocklet D, Lacroix S, Cnop M, Fery F, Aelst NV, Pilcer G, Deleers M, Goldman S, Amighi K. 2012. Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients. Eur J Pharm Biopharm 80(1):4-13.
27. Shah VP, Tsong Y, Sathe P, Liu JP. 1998. In vitro dissolution profile comparison-statistics and analysis of the similarity factor f2. Pharm Res 15:889-896.
28. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. 2002. Trojan particles: Large porous carriers of nanoparticles for drug delivery. PNAS 99(19):12001-12005.
29. Steckel H, Brandes HG. 2004. A novel spray-drying technique to produce low density particles for pulmonary delivery. Int J Pharm 278(1):187-195.
30. Nolan LM, Tajber L, McDonald BF, Barham AS, Corrigan OI, Healy AM. 2009. Excipient-free nanoporous microparticles of budesonide for pulmonary delivery. Eur J Pharm Sci 37(5):593-602.
31. Pilcer G, Wauthoz N, Amighi K. 2012. Lactose characteristics and the generation of the aerosol. Adv Drug Deliv Rev 64(3):233-256.
32. De Boer AH, Winter HMI, Lerk CF. 1996. Inhalation characteristics and their effect on in-vitro drug delivery from dry powder inhalers. Int J Pharm 130:231-244.
33. Meakin BJ, Ganderton D, Panza I, Ventura P. 1998. The effect of flow rate on drug delivery from the Pulvinal, a high resistance dry powder inhaler. J Aerosol Med 11(3):143-152.